Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments

The Harmonising Outcome Measures for Eczema (HOME) initiative has recommended a Core Outcome Set (COS) for atopic eczema clinical trials. Adherence to this COS in future clinical trials of atopic eczema treatments will ensure outcomes are measured and reported consistently, thus allowing direct comparison and minimizing bias. The COS consists of domains (what should be measured) and instruments (howto measure it). In 2011 four core domains were agreed: (i) clinician-reported signs, (ii) patient-reported symptoms, (iii) dermatology-specific quality of life (QoL) and (iv) long-term control. The Eczema Area and Severity Index (EASI) (2013)and Patient-Oriented Eczema Measure (POEM) (2015) are the agreed instruments for signs and symptoms, respectively. EASI combines the severity of the signs of eczema with the extent to which the body is affected, and POEM is a seven-item questionnaire that captures the frequency of symptoms of eczema experienced over the previous week. Using the World Health Organization International Clinical Trials Registry Plat-form (WHO ICTRP), a network of international clinical trials registers, we sought to quantify uptake of the HOME core outcomes in clinical trials over time.


R. Vincent J.R. Chalmers C. McWilliams K.S. Thomas S. Dodd N. Rogers M.J. Ridd J. Schmitt J.J. Kirkham


Journal: The British Journal of Dermatology
Volume: 183
Issue: 3
Pages: 566 - 568
Year: 2020
DOI: 10.1111/bjd.19030

Further Study Information

Current Stage: Completed
Funding source(s): M.J.R. is funded by a postdoctoral research fellow-ship from the National Institute of Research (NIHR) (PDF-2014-07-013)

Health Area

Disease Category: Skin

Disease Name: Eczema

Target Population

Age Range: 0 - 100

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

Study Type

- COS methods research


- Literature review

Linked Studies

Related Links

    No related links